Capecitabine Brands

Roche's oral fluoropyrimidine chemotherapy (capecitabine) developed by Genentech, FDA approved April 30, 1998, as the first oral chemotherapy for metastatic breast cancer and later for metastatic colorectal cancer, now available as generic capecitabine following patent expiration.